Get 20% Off All Market Studies With Code ONLINE20 – Anticipate Tariff Impacts, Market Disruptors, and Long-Term Growth Trends
What Is the Expected Market Growth Rate for the Alopecia Treatment Market?
The alopecia treatment market size has grown strongly in recent years. It will grow from $9.56 billion in 2024 to $10.12 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increasing prevalence of alopecia, aging population, hormonal changes, genetic predisposition, rising awareness about hair loss treatments, growth in cosmetic and dermatology industries and improved healthcare access.
The alopecia treatment market size is expected to see strong growth in the next few years. It will grow to $12.94 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing adoption of non-invasive treatments, growing demand for personalized medicine, increasing focus on mental health and self-esteem, rising consumer awareness about hair loss causes and treatments and increasing clinical trials for alopecia therapies. Major trends in the forecast period include the advancement of stem cell-based hair regeneration, use of platelet-rich plasma (PRP) therapy, development of jake inhibitors for autoimmune alopecia, innovations in laser hair therapy, and wearable devices for hair growth stimulation.
Claim your free report sample now:
Which Major Growth Factors Are Shaping the Alopecia Treatment Market?
The increasing prevalence of hair loss is expected to propel the growth of the alopecia treatment market going forward. Hair loss refers to the condition where an individual experiences the partial or complete loss of hair from the scalp or other parts of the body. The prevalence of hair loss is increasing due to rising stress levels, which can disrupt the normal hair growth cycle and trigger conditions such as telogen effluvium, leading to excessive hair shedding. As more individuals seek effective solutions to manage and reverse hair loss, the demand for advanced and accessible alopecia treatments is rising. For instance, in October 2024, according to the American Academy of Dermatology, a US-based professional medical association focused on dermatology, 80 million Americans were affected by hair loss, including 50 million men and 30 million women. Therefore, the increasing prevalence of hair loss is driving the growth of the alopecia treatment market.
What Are the Emerging Segments in the Alopecia Treatment Market?
The alopecia treatment market covered in this report is segmented –
1) By Dosage Form: Drug Therapy, Hair Transplant Services, Low-Level Laser Therapy
2) By Route of Administration: Topical, Injectable, Oral
3) By Indication: Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Alopecia Barbae, Chemotherapy Induced Alopecia, Other Indications
4) By Gender Type: Male, Female
5) By End User: Hospitals And Physicians Offices, Dermatology Clinics, Other End Users
Subsegments:
1) By Drug Therapy: Topical Solutions, Oral Medications, Injectable Treatments, Immunosuppressants, Janus Kinase Inhibitors
2) By Hair Transplant Services: Follicular Unit Transplantation (FUT), Follicular Unit Extraction (FUE), Robotic Hair Transplantation, Direct Hair Implantation (DHI)
3) By Low-Level Laser Therapy (LLLT): Laser Helmets, Laser Combs, Laser Caps, In-Clinic Laser Devices
Which Trends Are Most Likely to Influence Alopecia Treatment Market Growth in the Next Decade?
Major companies operating in the alopecia treatment market are focusing on developing innovative solutions such as oral small-molecule kanus kinase (JAK) inhibitors to enhance treatment efficacy, accelerate hair regrowth, and offer targeted therapy for patients with severe or resistant forms of alopecia areata. Oral small-molecule janus kinase (JAK) inhibitors are a class of targeted pharmaceutical drugs designed to block the activity of one or more of the Janus kinase enzymes (JAK1, JAK2, JAK3, and TYK2). For instance, in July 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, received a US Food and Drug Administration (FDA) approval for LEQSELVI, an oral Janus kinase (JAK) inhibitor, for the treatment of adults with severe alopecia areata. It is a selective inhibitor of JAK1 and JAK2 enzymes, which are involved in the immune system's attack on hair follicles in this autoimmune disorder. The recommended dosage is 8 mg orally twice daily, with or without food. This approval of LEQSELVI offers a new, effective treatment option for individuals suffering from this condition, which can have profound physical, emotional, and social impacts.
Which Companies Hold the Largest Share in the Alopecia Treatment Market?
Major companies operating in the alopecia treatment market are Pfizer Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Inc., Incyte Corporation, Hims & Hers Health Inc., Bosley Inc., Hair Club Co., Dermavant Sciences Inc., Histogen Inc., Capillus llc, Aclaris Therapeutics Inc., Nutrafol, Alvi Armani Co, Rogaine, Theradome Inc., Viviscal Ltd, Arena Pharmaceuticals Ltd, Cassiopea SA, Follica Inc., RepliCel Life Sciences Inc., HairClone Ltd, Revian Inc., Nioxin.
Get the full alopecia treatment market report here:
Which Regions Are Driving the Most Demand in the Alopecia Treatment Market?
North America was the largest region in the alopecia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alopecia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment